SCHEDULE 13D/A: Malone Wealth Ventures Discloses 17.8% Stake in Quantum Biopharma, Advisor Kevin Malone Increases Holdings

Malone Wealth Ventures LLC and its President and CEO, Kevin Malone, have disclosed a beneficial ownership of 17.8% of Quantum Biopharma Ltd.'s common stock, with Mr. Malone also serving as an Advisor to the Board.

Summary

• Malone Wealth Ventures LLC and Kevin Malone collectively beneficially own 610,371 shares of Quantum Biopharma Ltd. Common Stock.
• This represents 17.8% of the issuer's outstanding common stock.
• The shares were acquired through open market purchases by Malone Wealth Ventures LLC using client funds and through grants to Kevin Malone for his role as Advisor to the Board.
• Kevin Malone received an initial grant of 30,000 shares and an additional 60,000 shares as compensation for his advisory role.
• The purpose of the acquisition is for investment, with Kevin Malone's advisory role potentially influencing strategic direction, financing, capitalization, and corporate governance.
• Malone Wealth Ventures LLC executed multiple purchases and one sale of Quantum Biopharma shares on June 23, 2025, with purchase prices ranging from $22.18 to $29.19 per share and one sale at $22.549 per share.

Sentiment

Score: 7

Explanation: The filing indicates a significant and active investment by Malone Wealth Ventures and Kevin Malone, who also holds an advisory role, suggesting confidence and potential for strategic influence. The acquisition of a 17.8% stake is a strong positive signal, although the document is purely factual about ownership and intent, not performance.

Positives

• Malone Wealth Ventures LLC and Kevin Malone have accumulated a significant beneficial ownership stake of 17.8% in Quantum Biopharma Ltd., indicating strong conviction in the company.
• Kevin Malone, President and CEO of Malone Wealth Ventures, serves as an Advisor to the Board of Directors, providing a direct channel for influence on strategic direction, financing, capitalization, and corporate governance.
• Mr. Malone received 90,000 shares as compensation for his advisory role, aligning his interests with the company's performance.

Risks

• The Reporting Persons may acquire additional securities or dispose of some or all of their holdings, depending on market conditions, investment strategies, or other factors, which could impact share price volatility.

Future Outlook

The Reporting Persons may, from time to time, acquire additional securities of Quantum Biopharma Ltd. or dispose of some or all of their reported holdings, contingent on market conditions, investment strategies, or other factors. No further share grants have been discussed for the future.

Management Comments

• The securities were acquired for investment purposes.
• Kevin Malone serves as Advisor to the Board of Directors of the issuer and may, in such capacity, participate in discussions relating to strategic direction, financing, capitalization, or corporate governance.
• The Reporting Persons may be deemed to have an intent to influence the control of the issuer.
• At this time, no other grants have been discussed in the future.

Industry Context

This filing indicates a significant ownership stake by an investment advisory firm and its principal in Quantum Biopharma Ltd., a company in the biopharma sector. Such substantial ownership by an entity with an advisory role suggests a potential for active engagement in the company's strategic direction, which is a common practice among institutional investors seeking to maximize value in specialized industries like biopharma.

Corporate Governance

Related Party Transactions

• Kevin Malone received 30,000 shares as initial compensation for his role as Advisor to the Board of Directors of Quantum Biopharma Inc., pursuant to a consulting agreement.
• An additional 60,000 share grant was received by Kevin Malone based on continuation of work as Advisor to the Board.

Stakeholder Impact

• Shareholders: The significant ownership stake (17.8%) by Malone Wealth Ventures and Kevin Malone, coupled with Mr. Malone's advisory role, could be viewed positively as it suggests strong alignment of interests and potential for active engagement in strategic decisions.
• Management/Board: Kevin Malone's role as an Advisor to the Board and the Reporting Persons' intent to influence control indicate a more engaged and potentially demanding relationship with the company's management and board.

Next Steps

• Reporting Persons may acquire additional securities of Quantum Biopharma Ltd.
• Reporting Persons may dispose of some or all of their current holdings.
• Kevin Malone may continue to participate in discussions relating to strategic direction, financing, capitalization, or corporate governance as an Advisor to the Board.

Key Dates

Keywords

Quantum Biopharma Ltd., Malone Wealth Ventures LLC, Kevin Malone, Schedule 13D, Beneficial Ownership, Common Stock, Investment Advisory, Corporate Governance, Biopharma, Shareholder Activism, SEC Filing